by Admin | Jun 5, 2019 | Portfolio News
PHOENIX – June 5, 2019 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company founded on the myxoma virus (MYXV) platform from Arizona State University (ASU), announced today the completion of a $25 million series A financing led by Boehringer...
by Admin | May 2, 2019 | Portfolio News
CAMPBELL, Calif., May 2, 2019 /PRNewswire/ — Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its...
by Admin | Apr 23, 2019 | Portfolio News
SAN CARLOS, Calif., April 23, 2019 /PRNewswire/ — BAROnova, Inc., a medical device company focused on the development of first-in-class non-surgical solutions for the treatment of obesity, announced today that the U.S. Food and Drug Administration (FDA) has...
by Admin | Apr 11, 2019 | Portfolio News
BOSTON, April 11, 2019 /PRNewswire/ — Intrinsic Therapeutics, Inc., a medical device company focusing on surgeries to treat leg and low back pain resulting from ruptured lumbar discs with large anular defects, today announced a $52m Series Growth equity...
by Admin | Apr 9, 2019 | Portfolio News
2019年4月9日，卢凯制药和西班牙菲尔若制药集团宣布，就Ozenoxacin药品在大中华地区、香港和澳门地区的商业拓展共同签署独家协议。 卢凯制药创始人兼CEO罗北纬 与菲尔若制药集团亚太地区总负责人Marcel Autonell Vilaró签署协议 Ozenoxacin（其他国家商品名为Ozanex、Dubine和Xepi）是一种治疗脓疱的新抗生素。在美国、加拿大和欧洲的11个国家，该药品已被批准用于治疗成人和儿科患者的脓疱病。...
by Admin | Feb 12, 2019 | Portfolio News
February 12, 2019 Intrinsic Therapeutics has won FDA premarket approval for its Barricaid anular closure device intended for preventing reherniation, according to a recent FDA posting. The approval comes despite the fact that the prosthesis, which is designed for...
